在NSCLC和COVID-19中Icariside II:网络药理学和分子对接研究
Qing Kong1,2,3, Huahe Zhu1,2, Jingcheng Dong1,2
1Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
The journal of gene medicine
|July 5, 2024
概括
伊卡里赛德II (IS) 通过向关键的炎症和细胞过程,显示出治疗COVID-19非小细胞肺癌 (NSCLC) 患者的潜力. 这种黄类化合物可能会改善现有的抗癌和抗炎疗法.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
背景情况:
- 非小细胞肺癌 (NSCLC) 患者容易受到COVID-19的感染,治疗选择有限.
- 伊卡里西德II (IS) 是一种来自Epimedium的黄类化合物,具有抗癌,抗炎和免疫调节的特性.
- 这项研究调查了IS在治疗与COVID-19同时感染的NSCLC患者中的潜力.
研究的目的:
- 评估Icariside II (IS) 对COVID-19非小细胞肺癌 (NSCLC) 患者的治疗效果.
- 阐明IS作用在NSCLC/COVID-19中的潜在分子机制.
- 确定结合NSCLC和COVID-19治疗的潜在治疗点.
主要方法:
- 对NSCLC和COVID-19共同目标的综合分析.
- 生存分析和考克斯回归用于预后评估.
- 网络药理学,包括基因本体学和KEGG丰富分析.
- 蛋白质与蛋白质相互作用网络的构建和分子对接用于目标验证.
主要成果:
- 确定了NSCLC/COVID-19中IS治疗的关键目标:F2,SELE,MMP1,MMP2,AGTR1和AGTR2,具有有利的分子对接结果.
- 网络药理学表明IS影响白细胞迁移,炎症和活性氧物种代谢.
- IS可能调节关键信号通路,包括IL-17,TNF和HIF-1.
结论:
- 伊卡里赛德II (IS) 证明了作为COVID-19的NSCLC患者的辅助疗法的潜力.
- 它可能会增强当前抗癌和抗炎治疗的疗效.
- 对IS的进一步研究可能会为这种患者群体改善治疗策略.
更多相关视频
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.2K
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
550
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
